Loading
Life sciences · Journal article
Vox Sanguinis · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background and Objectives Massive transfusion (MT) is a lifesaving intervention for severe hemorrhage. Contemporary data on indications, transfusion practices, and outcomes across a broad in‐hospital population remain limited. Materials and Methods This retrospective cohort study included adult patients receiving MT at Karolinska University Hospital between 2016 and 2021. MT was defined as transfusion of ≥10 red blood cell (RBC) units within 24 h. Data were obtained from the hospital transfusion registry and medical records. Results A total of 486 MT events were identified. Median age was 60 years (interquartile range [IQR] 46–70), and 65.6% of patients were male. The most common indications were trauma (15.6%), abdominal cancer surgery (15.0%), cardiothoracic surgery (14.0%), and vascular surgery (12.3%). The overall median RBC:plasma:platelet ratio was 5:5:1, consistent with balanced transfusion strategies. MT was more frequently associated with acute than elective procedures (67.2% vs. 32.8%, p < 0.001). Fibrinogen, tranexamic acid, and prothrombin complex concentrate were administered in 69.5%, 52.1%, and 13.6% of cases, respectively. Mortality was 10.3% at 24 h and 31.7% at 30 days. The annual number of MT events decreased significantly during the study period ( p < 0.001), corresponding to an approximately 40% reduction between 2016 and 2021. Conclusion MT was required across a wide range of surgical and medical specialties and remained associated with substantial mortality. Balanced transfusion strategies were well implemented, whereas the use of adjunct hemostatic therapies varied considerably. The marked reduction in MT events over time suggests improvements in hemorrhage management and bleeding control.